UBS lowered the firm’s price target on Coherent to $4 from $7 and keeps a Buy rating on the shares. The transition towards a focus on oncology in the business mix will be the key driver for the stock, and feels Coherus’ recent steps extend cash runway, while revenue growth from Udencya and Loqtorzi can drive stock upside from these levels, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COHR:
- Coherent Introduces a New Circulator Adaptor Enabling Bi-Directional Fiber Connectivity For AI/ML Applications
- Coherent Debuts 800 Gbps QSFP Form Factor Transceiver Module for IP-over-DWDM Applications
- Coherent Introduces Industry-First I-temp 100G ZR QSFP28-DCO Module for Expanded Application in Edge and Access Networks
- Coherent Unveils New Diode Laser Bar for Improved Outcomes in Hair Removal
- Coherent Introduces Wavemaker® and Waveshaper® Optical Solutions for Multi-Wavelength Transmissions
